Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP4Z1 | Q86W10 | 4/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832577 | 0.89 | SMPD1 (0.38) | SMPD1CYP19A1SLC9A1CYP4Z1 | |
| SCHEMBL21946885 | 0.88 | SMPD1 (0.37) | SMPD1CYP19A1SLC9A1 | |
| SCHEMBL25977052 | 0.78 | NOTUM (0.37) | SMPD1CYP19A1 | |
| SCHEMBL25982633 | 0.78 | NOTUM (0.37) | SMPD1CYP19A1 | |
| SCHEMBL18972971 | 0.76 | DPP4 (0.33) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL4224858 | 0.73 | SMPD1 (0.66) | SMPD1HRH4HRH3DPP4 | |
| SCHEMBL23979222 | 0.73 | GABRA2 (0.36) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL18077443 | 0.72 | GABRA2 (0.35) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL23119145 | 0.71 | SMPD1 (0.41) | SMPD1CYP19A1 | |
| SCHEMBL10089709 | 0.70 | GABRA2 (0.42) | HRH4HRH3DPP4GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190254973-A1 | COMBINING ORTHOGONAL CHEMISTRIES FOR PREPARATION OF MULTIPLEXED NANOPARTICLES | VERILY LIFE SCIENCES LLC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190254973-A1 | COMBINING ORTHOGONAL CHEMISTRIES FOR PREPARATION OF MULTIPLEXED NANOPARTICLES | CD47, AGO2, EEA1 | SMPD1 599/4885HRH4 4171/4885HRH3 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.